Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples